[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Helou et al., 2023 - Google Patents

Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells

Helou et al., 2023

View PDF
Document ID
10808242046065517499
Author
Helou D
Quach C
Fung M
Painter J
Hurrell B
Loh Y
Howard E
Shafiei-Jahani P
Soroosh P
Sharpe A
Akbari O
Publication year
Publication venue
Journal of Allergy and Clinical Immunology

External Links

Snippet

Background Neutrophilic asthma is associated with disease severity and corticosteroid insensitivity. Novel therapies are required to manage this life-threatening asthma phenotype. Programmed cell death protein-1 (PD-1) is a key homeostatic modulator of the immune …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Sefik et al. A humanized mouse model of chronic COVID-19
Méndez-Enríquez et al. Mast cells and their progenitors in allergic asthma
Coquet et al. Interleukin-21-producing CD4+ T cells promote type 2 immunity to house dust mites
Winkler et al. Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients
Massoud et al. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells
Göbel et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells
Zohar et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis
Pandya et al. Circulating T helper and T regulatory subsets in untreated early rheumatoid arthritis and healthy control subjects
Barros et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase
Ito et al. IL-22 induces Reg3γ and inhibits allergic inflammation in house dust mite–induced asthma models
Ayano et al. Increased CD226 expression on CD8+ T cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis
Helou et al. Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells
Xie et al. Characterization of a novel mouse model with genetic deletion of CD177
Lunding et al. Poly (inosinic-cytidylic) acid–triggered exacerbation of experimental asthma depends on IL-17A produced by NK cells
Wang et al. Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increases IL‐17RB, which regulates basophil apoptosis and degranulation
Salem et al. Exacerbated intestinal inflammation in P2Y6 deficient mice is associated with Th17 activation
Qu et al. TLR4-RelA-miR-30a signal pathway regulates Th17 differentiation during experimental autoimmune encephalomyelitis development
AU2021201241B2 (en) Methods and compositions for modulating TH-GM cell function
Seelige et al. Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection
Tischner et al. Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation
McDonald et al. Nogo receptor is involved in the adhesion of dendritic cells to myelin
TWI572358B (en) Alpha-enolase specific antibodies and methods of use in immune diseases
Esnault et al. Increased IL‐6 and Potential IL‐6 trans‐signalling in the airways after an allergen challenge
Cribbs et al. Dissecting the role of BET bromodomain proteins BRD2 and BRD4 in human NK cell function
Mehrotra et al. Poly‐ADP‐ribosyl polymerase‐14 promotes T helper 17 and follicular T helper development